1. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents.
- Author
-
Zhang, Juan, Liu, Xuliang, Sa, Na, Zhang, Jin-He, Cai, Yong-Si, Wang, Kai-Ming, Xu, Wei, Jiang, Cheng-Shi, and Zhu, Kong-Kai
- Subjects
- *
BIOSYNTHESIS , *EPIDERMAL growth factor receptors , *PROTEIN arginine methyltransferases , *ANTINEOPLASTIC agents , *CANCER cell proliferation - Abstract
Protein arginine methyltransferase 5 (PRMT5) and epidermal growth factor receptor (EGFR) are both involved in the regulation of various cancer-related processes, and their dysregulation or overexpression has been observed in many types of tumors. In this study, we designed and synthesized a series of 1-phenyl-tetrahydro-β-carboline (THβC) derivatives as the first class of dual PRMT5/EGFR inhibitors. Among the synthesized compounds, 10p showed the most potent dual PRMT5/EGFR inhibitory activity, with IC 50 values of 15.47 ± 1.31 and 19.31 ± 2.14 μM, respectively. Compound 10p also exhibited promising antiproliferative activity against A549, MCF7, HeLa, and MDA-MB-231 cell lines, with IC 50 values below 10 μM. Molecular docking studies suggested that 10p could bind to PRMT5 and EGFR through hydrophobic, π-π, and cation-π interactions. Furthermore, 10p displayed favorable pharmacokinetic properties and oral bioavailability (F = 30.6%) in rats, and administrated orally 10p could significantly inhibit the growth of MCF7 orthotopic xenograft tumors. These results indicate that compound 10p is a promising hit compound for the development of novel and effective dual PRMT5/EGFR inhibitors as potential anticancer agents. [Display omitted] • Novel 1-phenyl-THβC derivatives were evaluated as first dual PRMT5/EGFR inhibitors. • Some derivatives significantly inhibited the proliferation of several cancer cell lines. • Compound 10p showed the best dual inhibition on PRMT5 and EGFR, and promising antiproliferative activity. • Compound 10p displayed favorable in vivo PK and PD properties. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF